Sanofi and GSK have entered into a collaborative effort with the U.S. government to accelerate the development and manufacturing of a COVID-19 recombinant protein-based vaccine. The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established pandemic adjuvant […]

Gene editing company CRISPR Therapeutics is building a new cell therapy manufacturing facility in Framingham, Massachusetts for clinical and commercial production of the company’s investigational cell therapy product candidates. “We look forward to building a state-of-the-art manufacturing facility, which will accelerate our programs and allow us to scale for commercial supply. We are thankful for […]

AstraZeneca and Daiichi Sankyo have entered into a global development and commercialization agreement for Daiichi Sankyo’s DS-1062, a TROP2 directed DXd antibody drug conjugate (ADC). DS-1062 is currently in phase 1 clinical development for non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC). Daiichi Sankyo and AstraZeneca will jointly develop and commercialize DS-1062 […]

The Massachusetts Biotechnology Council has released its 2020 Industry Snapshot report, which shows that the Massachusetts biopharma industry raised $2.1 billion in venture capital (VC) investment in the first half of 2020. The IPO market also remained strong, with seven IPOs from Massachusetts biotech companies in the first half of 2020, making up 33% of all […]

Watertown-based, clinical-stage biotech Pandion Therapeutics has announced the initial public offering of 7,500,000 shares of its common stock at a public offering price of $18.00 per share, for gross proceeds of $135 million. The common stock is expected to begin trading on the Nasdaq Global Market on July 17, 2020 under the symbol “PAND.” The offering is expected to close on July […]